Journal
BIOMOLECULES
Volume 12, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/biom12121802
Keywords
Alzheimer's disease; A beta; lncRNAs; biomarkers; therapeutics
Categories
Funding
- Jilin Medical and Health Talents Special Project
- Jilin Science and Technology Development Program [JLSWSRCZX2021-007]
- Jilin Health Care Commission Technological Innovation Project [YDZJ202201ZYTS100]
- [2019J003]
Ask authors/readers for more resources
This article discusses the unique regulatory functions of lncRNAs in Alzheimer's disease, focusing on their interaction with critical molecules and their potential applications in diagnosis and treatment.
Alzheimer's disease (AD) is the most common type of dementia, but its pathogenesis is not fully understood, and effective drugs to treat or reverse the progression of the disease are lacking. Long noncoding RNAs (lncRNAs) are abnormally expressed and deregulated in AD and are closely related to the occurrence and development of AD. In addition, the high tissue specificity and spatiotemporal specificity make lncRNAs particularly attractive as diagnostic biomarkers and specific therapeutic targets. Therefore, an in-depth understanding of the regulatory mechanisms of lncRNAs in AD is essential for developing new treatment strategies. In this review, we discuss the unique regulatory functions of lncRNAs in AD, ranging from A beta production to clearance, with a focus on their interaction with critical molecules. Additionally, we highlight the advantages and challenges of using lncRNAs as biomarkers for diagnosis or therapeutic targets in AD and present future perspectives in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available